학술논문
Off-label use of rituximab in dermatology: pemphigus treatment
Document Type
other
Author
Source
Anais Brasileiros de Dermatologia. August 2013 88(4)
Subject
Language
English
ISSN
0365-0596
Abstract
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.